Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
Saved in:
| Title: | Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States. |
|---|---|
| Authors: | Borse RH; Merck & Co., Inc., Kenilworth, NJ, USA., Ramakrishnan K; Merck & Co., Inc., Kenilworth, NJ, USA., Gandhi J; CHEORS, North Wales, PA, USA., Dhankhar P; CHEORS, North Wales, PA, USA., Chirovsky D; Merck & Co., Inc., Kenilworth, NJ, USA. |
| Source: | Journal of medical economics [J Med Econ] 2022 Jan-Dec; Vol. 25 (1), pp. 954-965. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 9892255 Publication Model: Print Cited Medium: Internet ISSN: 1941-837X (Electronic) Linking ISSN: 13696998 NLM ISO Abbreviation: J Med Econ Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1941-837X |
|---|---|
| DOI: | 10.1080/13696998.2022.2095826 |
